Literature DB >> 2332596

Phenobarbital hepatotoxicity in an 8-month-old infant.

E A Roberts1, S P Spielberg, M Goldbach, M J Phillips.   

Abstract

Severe hepatotoxicity from phenobarbital occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis. Skin rash began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after phenobarbital had been started. Signs of severe liver disease included elevated aminotransferases, conjugated hyperbilirubinemia, significant coagulopathy, hepatosplenomegaly and ascites. Other features of this adverse drug reaction were unremitting fever, leukocytosis with eosinophilia and atypical lymphocytosis, and proteinuria. Sepsis, viral hepatitis, and metabolic liver disease were excluded. The child was on no other medication and had been previously well. In-vitro rechallenge of the patient's lymphocytes with cytochrome P-450 generated metabolites of phenobarbital showed extensive cytotoxicity compared to control. These data support the hypothesis that a defect in drug detoxification was responsible for the child's susceptibility to this drug hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2332596     DOI: 10.1016/0168-8278(90)90058-y

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  3 in total

1.  Fatal anticonvulsant hypersensitivity syndrome in an infant.

Authors:  Chih-Jung Chen; Yhu-Chering Huang; Chuan-Yu Wang; Tzou-Yien Lin
Journal:  Eur J Pediatr       Date:  2003-09-20       Impact factor: 3.183

2.  Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.

Authors:  Jean P Molleston; Robert J Fontana; M James Lopez; David E Kleiner; Jiezhun Gu; Naga Chalasani
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-08       Impact factor: 2.839

Review 3.  Drug-induced liver injury: is it somehow foreseeable?

Authors:  Giovanni Tarantino; Matteo Nicola Dario Di Minno; Domenico Capone
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.